专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

BR112022015141A2 MÉTODOS DE DIAGNÓSTICO E TRATAMENTO DE PACIENTES COM CARCINOMA DE CÉLULAS ESCAMOSAS CUTÂNEO 未知
公开(公告)号：BR112022015141A2
公开(公告)日：2022-10-11
申请号：BR112022015141
申请日：2021-02-01
申请人： CASTLE BIOSCIENCES INC , ROBERT WILLIS COOK , KYLE R COVINGTON , DEREK MAETZOLD , SARAH J KURLEY
发明人： ROBERT WILLIS COOK , KYLE R COVINGTON , DEREK MAETZOLD , SARAH J KURLEY
IPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q1/6813 , C40B30/04 , C40B40/08
摘要： MÉTODOS DE DIAGNÓSTICO E TRATAMENTO DE PACIENTES COM CARCINOMA DE CÉLULAS ESCAMOSAS CUTÂNEO. A presente invenção refere-se a métodos para prever o risco de recorrência e/ou metástase, ou ambos, no carcinoma de células escamosas cutâneo primário (cSCC).

2. 发明申请

US20070219825A1 METHOD OF MANAGING AND REDUCING SIDE EFFECTS ASSOCIATED WITH EXPOSURE TO A DRUG 审中-公开
标题翻译：管理和减少与药物接触相关的副作用的方法
公开(公告)号：US20070219825A1
公开(公告)日：2007-09-20
申请号：US11562457
申请日：2006-11-22
申请人： Derek Maetzold , Terrance Coyne
发明人： Derek Maetzold , Terrance Coyne
IPC分类号： G06Q10/00 , G06F7/00
CPC分类号： G06F19/3456 , G06Q50/22 , G16H50/30
摘要： A method for restricted distribution of a drug to a patient while minimizing the occurrence of adverse side effects. The method restricts access to the drug by preventing distribution to certain patients for whom the drug may be contraindicated. The method permits a prescription to be filled by a pharmacy only after the pharmacy has received an approval for release of the prescription. Generation of the prescription approval depends on registration of a prescriber, pharmacy and patient in a central database, and the determination that the risk is acceptable that the patient will experience an adverse side effect. The database contains a patient profile that may include additional patient-specific health-related information that is probative of the risk that an adverse side effect is likely to occur if the patient is exposed to the drug. Based in part on the information in the patient profile, the registered prescriber makes a determination as to the patient's risk of adverse side effects. If the registered prescriber determines that the risk is acceptable, a prescription request is generated. At the time that the prescription is to be dispensed to the patient, the pharmacy also makes a determination as to the patient's risk of adverse side effects. If the pharmacy determines that the risk is acceptable, the drug is dispensed to the patient. Additional steps may be taken to ensure compliance with the drug delivery method, such as education, oversight by a drug safety analyst, and/or regular contact with a representative.
摘要翻译：一种药物对患者的限制性分布的方法，同时使不良副作用的发生最小化。该方法通过阻止药物可能禁忌的某些患者的分布来限制药物的获取。该方法只有在药房收到处方批准后才能由药房填写处方药。处方批准的生成取决于处方人，药房和患者在中央数据库中的注册，以及确定患者将遭受不良副作用的风险是可接受的。数据库包含患者资料，其可以包括额外的患者特异性健康相关信息，其证明如果患者暴露于药物时可能发生不良副作用的风险。部分依据患者资料中的信息，注册的处方者对患者的不良副作用风险作出判断。如果注册的处方者确定风险是可接受的，则会生成处方请求。在将药方分配给患者的时候，药房也会确定患者有不良副作用的风险。如果药房确定风险是可以接受的，则药物被分配给患者。可采取额外步骤，以确保遵守药物递送方法，如教育，药物安全分析员的监督和/或与代表的定期接触。

3. 发明申请

US20140371081A1 Compositions for and Methods of Detecting, Diagnosing, and Prognosing Thymic Cancer 有权
标题翻译：检测，诊断和预后胸腺癌的组成和方法
公开(公告)号：US20140371081A1
公开(公告)日：2014-12-18
申请号：US14128279
申请日：2013-06-22
申请人： Sunil Badve , Yesim Gokmen-Polar , Patrick J. Loehrer , Robert Cook , Derek Maetzold
发明人： Sunil Badve , Yesim Gokmen-Polar , Patrick J. Loehrer , Robert Cook , Derek Maetzold
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57407
摘要： Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.
摘要翻译：提供生物标志物用于检测，诊断和预测具有胸腺癌或疑似胸腺癌的个体中的胸腺癌。此外，提供了用于测量表达水平的试剂盒或与胸腺癌相关的生物标志物的存在，用于检测，诊断和预测胸腺癌。此外，提供了用于通过生物标志物检测，诊断和预测具有或怀疑具有胸腺癌的个体的胸腺癌的方法。

4. 发明申请

US20200332363A1 METHODS FOR PREDICTING RISK OF RECURRENCE AND/OR METASTASIS IN SOFT TISSUE SARCOMA 审中-公开
公开(公告)号：US20200332363A1
公开(公告)日：2020-10-22
申请号：US16306018
申请日：2017-06-05
申请人： Robert Willis Cook , Weiwei Shan , Derek Maetzold , CASTLE BIOSCIENCES, INC.
发明人： Robert Willis COOK , Weiwei SHAN , Derek MAETZOLD
IPC分类号： C12Q1/6886
摘要： The disclosure related to the development of a gene expression profile to predict soft tissue sarcoma (STS) recurrence, distant metastasis, or both. Analyses identified a 36-gene gene expression profile able to accurately predict risk in a cohort of soft tissue sarcoma tumors independent of histologic and pathologic grade. This discovery offers an opportunity to enhance current staging of STS to identify patients who have a higher risk of recurring, distant metastasis, or both.

5. 发明授权

US10233502B2 Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer 有权
公开(公告)号：US10233502B2
公开(公告)日：2019-03-19
申请号：US14128279
申请日：2012-06-22
申请人： Sunil Badve , Yesim Gokmen-Polar , Patrick J. Loehrer , Robert Cook , Derek Maetzold
发明人： Sunil Badve , Yesim Gokmen-Polar , Patrick J. Loehrer , Robert Cook , Derek Maetzold
IPC分类号： C12Q1/6886 , G01N33/574
摘要： Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式